A compound of formula 1 wherein R 1 is a linear or branched C 1-6 -alkyl, wherein R 1 is substituted by R 3 which is selected from the group consisting of a three-, four-, five-, six- or seven-membered cycloalkyl; a five-, six- or seven-membered, saturated heterocycle comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; and a five- or six-membered heteroaryl comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; wherein R 3 may optionally be substituted by one, two, three or four substituents each independently selected from the group consisting of oxo, OH, -CO-NH 2, -CO-NH(CH 3), -CO-N(CH 3) 2, -C 1-5 -alkyl, -C 1-3 -alkylene-CO-NH 2, -C 1-3 -alkylene-CO-NH(CH 3), -C 1-3 -alkylene-CO-N(CH 3) 2 -C 1-3 -alkylene-CN and -CN, and wherein R 2 is selected from the group consisting of halogen, phenyl, a five- or six-membered monocyclic heteroaryl comprising one, two or three heteroatoms each independently selected from the group consisting ofN, S and O; a bicyclic nine-, ten- or eleven-membered, either aromatic or non-aromatic, but not fully saturated heterocycle comprising one, two, three or four heteroatoms each independently selected from the group consisting of N, S and O; wherein R 2 may optionally be substituted by one, two, three or four substituents R 4 which independently from one another are selected from the group consisting of linear or branched -O-C 1-5 -alkyl, -OH, oxo, halogen, -C 1-5 -haloalkyl, -SO 2 CH 3, -C 1-3 -alkylene-SO 2 -C 1-3 -alkyl), -SO 2 -CF 3, -CN, -C 3-6 -cycloalkyl, linear or branched -C 1-5 -alkyl, a four, five- or six-membered saturated heterocycle comprising one, two or three heteroatoms each independently from one another selected from the group of N, S, -SO 2 and O; -C 1-3 -alkylene-N(C 1-3 -alkyl)-CO-C 1-3 -alkyl, -NH-CO-C 1-3 -alkyl, -CO-NH(CH 3), -CO-NH 2, -CO-N(CH 3) 2, -O- R 5, -CO- R 5, -C 1-3 -alkylene-O-CO-C 1-3 -alkyl and wherein R 4 may optionally be substituted by one or two substituents R 5, wherein each R 5 is independently from one another selected from the group consisting of linear or branched -C 1-4 -alkyl, oxo,-C 1-3 -haloalkyl, -OH, halogen, -C 1-2 -alkylene-C 1-3 -haloalkyl, a five- or six-membered saturated heterocycle comprising one, two or three heteroatoms each independently selected from the group ofN, S and O, a three, four-, five-, six- or seven-membered cycloalkyl, a five- or six-membered heteroaryl comprising one or two heteroatoms each independently selected from the group consisting ofN, O and S, wherein R 5 may optionally be substituted by a group consisting of oxo,-C 1-3 -alkyl and -C 1-3 -haloalkyl, and the pharmacologically acceptable salts of the aforementioned compounds. R 1 is a linear or branched C 1-6 -alkyl, wherein R 1 is substituted by R 3 which is selected from the group consisting of a three-, four-, five-, six- or seven-membered cycloalkyl; a five-, six- or seven-membered, saturated heterocycle comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; and a five- or six-membered heteroaryl comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; wherein R 3 may optionally be substituted by one, two, three or four substituents each independently selected from the group consisting of oxo, OH, -CO-NH 2, -CO-NH(CH 3), -CO-N(CH 3) 2, -C 1-5 -alkyl, -C 1-3 -alkylene-CO-NH 2, -C 1-3 -alkylene-CO-NH(CH 3), -C 1-3 -alkylene-CO-N(CH 3) 2 -C 1-3 -alkylene-CN and -CN, and wherein R 2 is selected from the group consisting of halogen, phenyl, a five- or six-membered monocyclic heteroaryl comprising one, two or three heteroatoms each independently selected from the group consisting ofN, S and O; a bicyclic nine-, ten- or eleven-membered, either aromatic or non-aromatic, but not fully saturated heterocycle comprising one, two, three or four heteroatoms each independently selected from the group consisting of N, S and O; wherein R 2 may optionally be substituted by one, two, three or four substituents R 4 which independently from one another are selected from the group consisting of linear or branched -O-C 1-5 -alkyl, -OH, oxo, halogen, -C 1-5 -haloalkyl, -SO 2 CH 3, -C 1-3 -alkylene-SO 2 -C 1-3 -alkyl), -SO 2 -CF 3, -CN, -C 3-6 -cycloalkyl, linear or branched -C 1-5 -alkyl, a four, five- or six-membered saturated heterocycle comprising one, two or three heteroatoms each independently from one another selected from the group of N, S, -SO 2 and O; -C 1-3 -alkylene-N(C 1-3 -alkyl)-CO-C 1-3 -alkyl, -NH-CO-C 1-3 -alkyl, -CO-NH(CH 3), -CO-NH 2, -CO-N(CH 3) 2, -O- R 5, -CO- R 5, -C 1-3 -alkylene-O-CO-C 1-3 -alkyl and wherein R 4 may optionally be substituted by one or two substituents R 5, wherein each R 5 is independently from one another selected from the group consisting of linear or branched -C 1-4 -alkyl, oxo,-C 1-3 -haloalkyl, -OH, halogen, -C 1-2 -alkylene-C 1-3 -haloalkyl, a five- or six-membered saturated heterocycle comprising one, two or three heteroatoms each independently selected from the group ofN, S and O, a three, four-, five-, six- or seven-membered cycloalkyl, a five- or six-membered heteroaryl comprising one or two heteroatoms each independently selected from the group consisting ofN, O and S, wherein R 5 may optionally be substituted by a group consisting of oxo,-C 1-3 -alkyl and -C 1-3 -haloalkyl, and the pharmacologically acceptable salts of the aforementioned compounds.